Clinical Research Treatment White Paper 
Conversations in Drug Development Trends
JULY 29, 2024
Despite these advancements, challenges for widespread effective care remain due to the heterogeneous patient population, opening the door for further development of treatments for T2D. Obesity is a major factor in the prevalence of T2D, and it is vital to develop T2D treatments with this in mind.
Conversations in Drug Development Trends
MARCH 12, 2024
From their use in risk and safety assessments to patient screening and treatment efficacy, biomarkers offer minimally invasive, objective data. For a more in-depth look at biomarkers, check out our white paper. Deviations from established baseline values provide insights into treatment response in certain cancer indications.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Conversations in Drug Development Trends
MARCH 1, 2024
To help determine if a master protocol could be a good fit for your study, check out this white paper for a more comprehensive overview of the appropriateness of master protocols in different contexts. Here are some relevant factors below: What Are the Advantages of a Master Protocol? Contact us.
The Pharma Data
SEPTEMBER 11, 2020
In an effort to slow the spread of the disease and prevent a second wave, pharma companies around the world are continuously looking to advance new methods of treatment. DEP remdesivir enables subcutaneous or under the skin injections rather than intravenous infusion, allowing for outpatient treatments and reducing the burden on hospitals.
The Pharma Data
OCTOBER 16, 2020
With many nationwide and regional lockdowns coming into force, virtual clinical trials are proving to be an effective way to monitor patients remotely. BetterLife conducts patient centric study via a fully remote clinical trial. All of these technologies can be used on a variety of devices. Source link.
Conversations in Drug Development Trends
MARCH 20, 2024
As the study of how an individual’s genes affect their response to drugs, pharmacogenomics is a critical factor in developing effective and safe drugs and dosages in clinical trials. However, certain variants may not metabolize this blood thinner as efficiently, rendering the treatment less effective in those participants.
PPD
OCTOBER 12, 2023
These treatments use a vector to introduce the desired nucleic acid code to replace or modify protein expression or use cells to alter/restore a specific cell type. DOWNLOAD OUR WHITE PAPER Learn more about how PPD® Laboratory services can enhance your CGT projects.
Expert insights. Personalized for you.
52 
Let's personalize your content